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Abstract
Background: Rho kinase (ROCK) and myosin-light chain kinase (MLCK) are key enzymes in smooth muscle contraction.
Previous data have suggested that ROCK contribution to human detrusor contraction is increasing with age. Here, we
have analyzed the transcriptional expression of Rho kinase isoforms (ROCK1 and ROCK2) as well as MLCK in the aging
human detrusor smooth muscle obtained from resected tissue.
Methods: Small pieces of macroscopically healthy human detrusor smooth muscle (urothelium-free) were
prepared for quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR). Transcript
expression (mRNA level) of the target genes ROCK1, ROCK2 and MLCK was normalized to three common
reference genes (glyceraldehyde-3-phosphate dehydrogenase, β-actin, phosphoglycerate kinase 1).
Results: We found that across all ages the expression level of ROCK (i.e. ROCK1 and ROCK2 together) was
almost equal to that of MLCK in the human bladder. Further, ROCK2 showed a significantly higher expression
level than ROCK1. Among all subjects, there was no significant correlation of any single target gene to age,
but expression levels of ROCK and MLCK were inversely correlated. Moreover, the within-subject analysis
revealed that the ROCK-to-MLCK ratio showed a significantly negative correlation to age. Thus, within a
given subject, there is a relative ROCK down-regulation and concomitant MLCK up-regulation.
Conclusions: Together with previous data in human detrusor specimens showing increased ROCK
contribution to detrusor contraction, we speculate that the drop of the ROCK-to-MLCK ratio may occur as an
attempt to compensate for the increased Rho kinase activity.
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Background
Age-related changes in urinary bladder contractility are
believed to contribute to dysfunctional micturition such
as overactive bladder syndrome (OAB). This is a com-
mon urological condition associated with urgency, with
or without urge incontinence, and increased micturition
frequency and nocturia [1]. OAB prevalence increases
with age [2], and in order to find new therapeutic strat-
egies for the management of OAB it is crucial to unravel
the pathophysiological mechanisms leading to increased
bladder contractility. Hence, it is obvious that there is a
need for studies on contraction and relaxation mecha-
nisms in the aging human urinary bladder. During the
last decade several groups have focussed on the classical
adrenergic and cholinergic mechanisms of detrusor mo-
tility. For instance, detrusor relaxation following sympa-
thetic β-adrenoceptor activation was not altered during
aging [3], the same was true for cholinergic responses
[4]. Although there is no age-related correlation, current
medication is still based on antimuscarinics and β-
sympathomimetics. On the other hand, purinergic
receptor-mediated contraction increased with age [4]
and may thus be regarded as an attractive candidate
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mechanism. Beyond receptor activation, intracellular
contraction mechanisms could also be accessible targets
for pharmacological manipulation. We have recently ad-
dressed the key enzymes Rho kinase (ROCK) and
myosin-light chain kinase (MLCK) in the aging human
bladder and could demonstrate that ROCK contribution
to detrusor contractility was positively correlated with
age, while MLCK contribution was not altered during
aging [5]. Therefore, we hypothesized that transcrip-
tional up-regulation of Rho kinase could be responsible
for this age-related effect. To this end, we performed
quantitative real-time reverse transcriptase polymerase
chain reaction (RT-PCR) in order to determine the
mRNA expression levels of the two isoforms of Rho kin-
ase (ROCK1 and ROCK2) and MLCK in detrusor
smooth muscle tissue obtained from patients undergoing
cystectomy.
Methods
Preparation of detrusor smooth muscle strips
Human detrusor samples were obtained from 41 pa-
tients with an average age of 67 ± 10 years (mean ± S.D.;
range 46–84 years old; 33 male and 8 female patients,
Table 1). These specimens (1–2 cm width) were pre-
pared from surgically resected bladder wall obtained
from patients who underwent cystectomy. The indica-
tion for cystectomy was bladder cancer (urothelial car-
cinoma) with or without prostate cancer in 35/41 cases,
other malignancies with or without infiltration of the
urinary bladder in 4/41 cases and neurogenic bladder in
2/41 cases (Table 1). Care was taken to dissect only
macroscopically healthy bladder wall tissue for this
study, but the anatomical origin could not be standard-
ized due to requirements for routine histopathological
examinations especially in radical cystectomy. The speci-
mens always contained urothelium which was removed
before small pieces were cut for the PCR analysis. Thus,
the tissue used in this study was always obtained from
within the detrusor smooth muscle. All in vitro experi-
ments with human material performed in this study
were approved by the local ethics committee (University
of Rostock), and the informed consent to participate in
this study was obtained from each patient.
Quantitative RT-PCR analysis
Small pieces from the detrusor smooth muscle portion
of approx. 1–2 mm width were prepared from the
human tissue sample and immediately frozen in liquid
nitrogen. Care was taken that these pieces for quantita-
tive PCR were urothelium-free. For mRNA isolation,
TRIZOL reagent was used, and total RNA was
reverse-transcribed using Moloney murine leukemia
virus reverse transcriptase (200 U/μL) and RNasin Plus
RNase inhibitor (40 U/μL, both Promega Corporation,
Madison, WI, USA) in the presence of random hexamers
(3 μg/μL) and dNTP Mix (10 mmol/L each, Invitrogen,
Carlsbad, CA, USA). For the real-time PCR of the target
genes (Rho kinase 1 [ROCK1], Rho kinase 2 [ROCK2],
myosin-light chain kinase [MLCK]) as well as three
standard reference genes (glyceraldehyde-3-phosphate de-
hydrogenase [GAPDH], β-actin [ACTB], phosphoglycer-
ate kinase 1 [PGK1]), we used the QuantiFast SYBR
Green PCR Kit (concentration as recommended by the
manufacturer, Qiagen Inc., Valencia, CA, USA). The mas-
termix was aliquoted, cDNA and primers (Cf = 20 μmol)
were added. All primers purchased from Molbiol (Berlin,
Germany) are given in Table 2. The reference genes ACTB
and PGK1 were detected using Qiagen Primer Assays
(Qiagen Inc., Valencia, CA, USA). The PCR product
length was 156–285 bp (Table 2). Real-time PCR was per-
formed using the ep mastercycler (software realplex 2.2,
Eppendorf, Hamburg, Germany) with cycling parameters
95.0 °C for 2 minutes once, followed by 95.0 °C for 15 s
and the annealing temperature for 15 s, with normalized
fluorescence read at 68.0 °C (520 nm) for 40 cycles. The
annealing temperatures were adjusted using gradient PCR
(ROCK1/GAPDH 53.7 °C, ROCK1/ACTB/PGK1 57.5 °C,
ROCK2/GAPDH 62.6 °C, ROCK2/ACTB/PGK1 57.5 °C).
Single product amplification was confirmed by melting
curve and gel electrophoresis analysis. Then, the efficiency
was determined by PCR using serial dilution of the
cDNA. Messenger-RNA (mRNA) expression levels were
efficiency-corrected and determined by normalizing the
target genes (ROCK1, ROCK2, MLCK) with three stand-
ard reference genes (GAPDH, ACTB, PGK1), expressed
as the mean of 2-ΔΔCt ± SEM.
Statistics
All data are expressed as means ± SEM. Statistical com-
parison was performed using the two-tailed Student’s t-
test (SigmaStat 3.5). The level of significance is indicated
by asterisks (*P < 0.05; **P < 0.01).
Results
In the present study, we aimed to investigate the tran-
scriptional expression of Rho kinase (ROCK, isoforms
ROCK1 and ROCK2) and myosin-light chain kinase
(MLCK) in human detrusor smooth muscle using quan-
titative RT-PCR, normalized to three commonly used
reference genes (glyceraldehyde-3-phosphate dehydro-
genase [GAPDH], β-actin [ACTB], phosphoglycerate
kinase 1 [PGK1]). As it is shown in Fig. 1a, ROCK2
mRNA levels were significantly higher than ROCK1
mRNA levels (P < 0.01 for all three reference genes,
paired two-tailed t-test) indicating that ROCK2 is the
predominant Rho kinase isoform in human urinary blad-
der. The relative mRNA contribution was 15.2 ± 1.9 %
for ROCK1, 42.8 ± 3.8 % for ROCK2 and 41.9 ± 4.8 % for
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Table 1 Patient data
No. Age Sex Diagnosis and cystectomy indication Type of surgery History
1 68 m Bladder cancer G2 pT2b pN0 (0/9) L0 F0 R0 cM0 Radical cystectomy/
neobladder
S/P 1× TUR bladder G3 pT2a
2 66 w Bladder cancer pT1 G3 pN0 L0 V0 R0 M0 Radical cystectomy/Mainz
Pouch I
S/P 1× TUR bladder G2 pT1 and Cis
3 61 m Bladder cancer pT3a pN0 cMx R0 G3 Carcinoma left renal
pelvis pT2 pN3 cMx R1 G3 Prostate cancer pT1a pN0 cMx




S/P 11× TUR bladder G2 pTa and Cis, at
least pT2 G3
4 80 m Bladder cancer pT2b (is) pN0 cM0 R0 L0 V0 G3 Prostate
cancer: pT2a pN0 (0/13) R0 L0 V0 Gleason: 3 + 3
Radical cystectomy/ileal
conduit
S/P 1 × TUR bladder G3, pT2a
5 68 m Bladder cancer pT1 (is) pN0 (0/12) G3 R0 L0 V0 Radical cystectomy/ileal
conduit
S/P 1× TUR bladder pT1 G3 and pTa G2
6 62 m Bladder cancer pT2b (is), pNo (0/20) G3 R0 L1 V0 cM0 Radical cystectomy/ileal
conduit
S/P 1× TUR bladder pT2a G3
7 73 m Bladder cancer (with adenoid vegetations) G3 pT1 pN0
(0/11) L0 V0 R0 M0 Prostate cancer G2 pT2c PN0 L0 V0 R0
M0 Gleason 3 + 2 = 5
Radical cystectomy/ileal
conduit
S/P 1× TUR-prostate (no malignancy) S/P 1x
TUR-bladder pT1 G3




S/P 1× TUR-bladder (necrotic urothelial
carcinoma)




S/P 6× TUR-bladder rpTa-1 G1-2, at least G3
pT2




S/P prostate biopsy pT1c Gleason 5 + 4 = 9
and suprapubic catheter after overflow
bladder
11 60 m Bladder cancer pT1 pN0 cM0 R0 G2 (high grade) Radical cystectomy/ileal
conduit
S/P 1× TUR bladder pTa G2 and pT1 G2
12 80 w Bladder cancer pT1 pN0 cM0 R0 G2 (high grade) Radical cystectomy with
urethrectomy/ileal conduit
no history available
13 68 m Neurogenic bladder (contracted bladder) Prostate cancer
pT2c R0 L0 V0; Gleason 3 + 3 = 6
Radical cystectomy/ ileal
conduit
Incomplete paraplegia Th4 Polyneuropathy
due to alcoholism S/P suprapubic catheter
14 74 m Bladder cancer pT1 pN2 (2/17) G3 R0 L1 V0 Radical cystectomy/ileal
conduit
no history available
15 59 m Bladder cancer pT3b pN2 (2/12) G3 R0 L1 V0 Radical cystectomy/
neobladder
S/P 2× TUR-bladder pT1 G2-3
(adenocarcinoma)
16 60 m Bladder cancer pTis pN0 (0/24) R0 M0 Renal pelvic cancer




S/P 1×TUR-bladder pTis with urothelial
carcinoma G2-3 and urothelial carcinoma
left renal pelvis G1 pTa
17 57 m Bladder cancer G3 pT1 pN0 (0/26) L0 V0 R0 cM0 Radical cystectomy/
neobladder
S/P 3× TUR-bladder G3, pTa and mrpTis
18 71 m Bladder cancer G3 pT3b pN2 (9/20) L1 V1 R0 cM1 Radical cystectomy/ileal
conduit
S/P 7× TUR-bladder pTa G2 and pT1G3 and
rpT1G3
19 74 m Bladder cancer G3 pT2a pN0 (0/5) L0 V0 R0 cM0 Prostate
cancer pT2 pN0 M0 G2
Radical cystectomy/ ileal
conduit
S/P 1× TUR-bladder mpT1 G3
20 72 m Bladder cancer pTX pN2 (3/12) G3 R0 cM0 Radical cystectomy/ileal
conduit
S/P TUR-bladder T2a G2-3
21 75 m Bladder cancer G3 pT3b pN0 (0/14) L1 V0 R1 cM0 Prostate
cancer Gleason: 4 + 5 = 9; G3 pT2c pN0 L0 V0
Radical cystectomy/ileal
conduit
S/P 1× TUR-bladder T2 G3, renal failure
22 56 m Bladder cancer G3 pT3a pN3 L1 V1 pM1 (LYM) Prostate
cancer Gleason 2 + 3 = 5; G2 pT2c
Radical cystectomy/ileal
conduit
S/P TUR-bladder T2 G3
23 77 m Bladder cancer G3 pT1 pN0 (0/13) L0 V0 R0 cM0 Prostate
cancer Gleason 3 + 4 = 7; G3 pT2a pN0 L0 V0 R0 M0
Radical cystectomy/ileal
conduit
S/P 4× TUR-bladder rpT1G2 and pTa G2
24 84 m Bladder cancer G3 pT2a pN0 (0/17) L0 V0 R0 cM0 Radical cystectomy/ileal
conduit
S/P 3× TUR-bladder pTa G1-2 and at least
pT2 G3
25 56 w Bladder cancer pT1 (is) pN0 cM0 R0 G3 V0 L0 Radical cystectomy/Mainz
Pouch I
S/P 1× TUR-bladder pT1 G3 and mpTis
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MLCK (Fig. 1b). When pooling the relative mRNA
quantification for ROCK1 and ROCK2, however, there
was no consistent difference between ROCK (i.e. ROCK1
and ROCK2 together) and MLCK expression (P > 0.05
for ACTB and PGK1, P < 0.05 for GAPDH, unpaired
two-tailed t-test) suggesting that ROCK and MLCK tran-
scripts were almost equally abundant (Fig. 1b).
Since we have previously found that Rho kinase
(ROCK) contribution to cholinergic detrusor contraction
increased with age [5], we hypothesized that expression
of this enzyme might be up-regulated in the aging de-
trusor. In order to test this, we performed a linear cor-
relation analysis between relative mRNA levels and age
(Fig. 2a,b). However, over the broad range of ages from
46 to 84 years we could not detect a significant correl-
ation between ROCK1 or ROCK2 to any reference gene
used (Fig. 2a,b). The Pearson’s correlation coefficients
for these bivariate analyses are given in Table 3. With
respect to the other key enzyme of smooth muscle
contraction, the correlation coefficient between MLCK
Table 1 Patient data (Continued)
26 80 w Bladder cancer G3 pT1 (is) pN0 (0/21) Mx V0 L0 R0 Radical cystectomy/ileal
conduit
S/P 1× TUR-bladder G3 pT1




S/P 1× TUR-urethra (squamous cell
carcinoma pTis)
28 52 m Bladder cancer pT3b pN2 (9/20) M1 (lymph) G3 R0 L1 V0
Prostate cancer pT2c pN0 cM0 R0 L0 V0 Gleason 3 + 4 = 7
Radical cystectomy/ileal
conduit
S/P 1× TUR-bladder G3 pT2
29 56 m Bladder cancer pT3a pN0 (0/25) G3 R0 L1 V0 cM0 Radical cystectomy/
neobladder
S/P 1× TUR-bladder G3 pT2 (is)
30 56 m Prostate cancer Gleason 4 (80 %) + 3 = 7; G3 pT4 pN1 (4/




31 76 w Bladder cancer pT3b pN1 (1/18) G3 R0 L1 V0 cM0 Radical cystectomy/ileal
conduit
S/P 1× TUR-bladder pT2 G3 S/P TFS (tissue
fixation system - sacrouterine ligament)




S/P 1× TUR-bladder pT2 G3 (squamous cell
carcinoma)
33 81 m Bladder cancer ypTis pN0 (0/17) R0 cM0 Prostate cancer
pT2a pN0 (0/17) R0 L0 V0, Gleason 3 + 3 = 6
Radical cystectomy/ileal
conduit
S/P 1× TUR-bladder pT1 (m, is) G2-3
34 63 m Cancer of prostatic duct Radical cystectomy/ileal
conduit
S/P mult. TUR-bladder (carcinoma in
prostatic duct)
35 74 m Bladder cancer pT1 pN0 cM0 R0 G2 V0 L0 Radical cystectomy/
neobladder
S/P1× TUR-bladder at least pT1 G3
36 59 m Bladder cancer G3 pT2(is) pN2 (3/25) pM1 (lymph) L1 V1
R0 Prostate adenocarcinoma G2, Gleason 3 + 3 = 6, pT2b
pN0 L0 V0 Pn1 R0
Radical cystectomy/
neobladder
S/P1× TUR-bladder mpT2 (is) L1 G2-3
37 76 m Bladder cancer and prostate cancer pT2c pN0 (0/18) R0 L0




38 68 w Neurogenic bladder, multiple sclerosis Cystectomy/ileal conduit Chronic pelvic pain, detrusor hyperactivity,
incomplete spastic paraplegia
39 51 m Bladder cancer pT4a (is) pN0 (0/16) G3 R0 L1 V0 cM0 Radical cystectomy/ileal
conduit
S/P 1× TUR-bladder G3, at least pT1 Nx M0
Nicotine abuse
40 84 m Bladder cancer G3 pT3a (is) pN0 (0/11) L0 V1 R0 cM0
Prostate adenocarcinoma Gleason 4 + 4 = 8, G3 pT2c pN0




41 74 m Bladder cancer G3 pT1 pN0 (0/18) L0 V0 R0 M0 Radical cystectomy/ileal
conduit
S/P G3, at least pT1 and carcinoma in situ.
S/P status post, TUR transurethral resection
Table 2 Forward and reverse primers of ROCK1, ROCK2, MLCK and GAPDH (from Molbiol). ACTB and PGK1 were detected with
Qiagen Primer Assays
Gene name Forward primer Reverse primer PCR product
ROCK1 AAAATTGTGTGAGGAGGACATGG TTCATCCCAACATTCTTGGATCT 279 bp
ROCK2 GCAATGCGGTAAAAAGCGA GGGAATCATGGTGTGACCAA 217 bp
MLCK GTCTTATGTTATCTTCCATTCTA TATAATAAACTGTGGCAATACTG 156 bp
GAPDH AGAAGGCTGGGGCTCATTTG AGGGGCCATCCACAGTCTTC 285 bp
Kirschstein et al. BMC Urology  (2015) 15:104 Page 4 of 9
normalized to ACTB and age reached statistical signifi-
cance (Fig. 3a, Table 3), but it is obvious that MLCK ex-
pression levels did not consistently show age-dependent
changes. One has to take into account that the vast ma-
jority of patients included in this study were cystecto-
mized due to bladder cancer. Thus, mRNA expression of
the analyzed contraction enzymes could be altered by
the adjacent tumor infiltration. We therefore performed
a regression analysis between the tumor size (patho-
logical tumor size, pT1-4 in Table 1) and mRNA expres-
sion, but did not obtain significant correlation (data not
shown). Since 33/41 (80 %) patients were male, we
tested whether there was a gender specificity in our data.
As also shown in Table 3, the correlation coefficients in
this subgroup analysis of male patients were similar to
those of the total study population. On the other hand,
the subgroup analysis for female patients did not reveal
statistically significant correlation coefficients either
(data not shown).
So far, we have not been able to find robust age-
dependent differences in mRNA abundance for ROCK1,
ROCK2 or MLCK. In these interindividual analyses,
however, we have plotted each individual against age and



















































































Fig. 1 Expression levels of the contraction enzymes Rho kinase (isoforms ROCK1 and ROCK2) and myosin light-chain kinase (MLCK) in the human
detrusor smooth muscle. a Relative mRNA content for target genes ROCK1 (white), ROCK2 (gray) and MLCK (black), expressed as percentage of
the reference genes GAPDH, ACTB and PGK1. Note that ROCK2 was significantly more expressed than ROCK1. b Relative mRNA abundance of
ROCK1, ROCK2 and MLCK. Note that expression level of ROCK1 and ROCK2 together was similar to that of MLCK
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within a given subject. We, therefore, calculated the
ROCK-to-MLCK ratio of every subject and plotted this
ratio against age. As shown in Fig. 3b, this analysis re-
vealed a decrease of the ROCK-to-MLCK ratio during
aging. This negative correlation was significant using all
three reference genes (Fig. 3b). Thus, we conclude that
there is a robust age-dependent drop of the ROCK-to-
MLCK ratio in the aging human detrusor smooth
muscle. Since ROCK2 was the predominant isoform in
human detrusor, we also calculated the correlation coef-
ficients for both isoforms separately (Table 3). These
analyses revealed that ROCK2-to-MLCK ratio is consist-
ently inversely related to age, but not the ROCK1-to-
MLCK ratio (Table 3). These data also suggest that
ROCK2 and MLCK are generally negatively correlated.
On average, the correlation coefficient between ROCK2
and MLCK mRNA levels was r = −0.5541 (n = 21, P < 0.01,
two-tailed t-test). In summary, across all subjects we found
an inverse relationship between ROCK and MLCK tran-
scription, respectively. Within a given subject, however,
aging was associated with a relative ROCK down-regulation
and concomitant MLCK up-regulation.
Discussion
Smooth muscle contraction involves activation of two
key enzymes – Rho kinase (ROCK) and myosin light-
chain kinase (MLCK). Both have been demonstrated in
human detrusor contraction [5], and the present study
was performed in order to quantify the mRNA levels for
the both isoforms of Rho kinase (ROCK1 and ROCK2)






































































Fig. 2 Expression of ROCK1 and ROCK2 is not correlated with age. Relative mRNA content for the target genes ROCK1 (a) and ROCK2 (b),
normalized to reference genes GAPDH, ACTB and PGK1 plotted against the patients’ age (n = 41). There was no significant correlation between
any of these target genes and age
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Quantified PCR data do necessarily depend on the
choice of reference genes used for normalization. In
particular, altered expression of a reference gene is a
potential pitfall in PCR studies that may substantially
contaminate the quantification of the genes of interest.
With respect to the present study, selection of reference
genes in human bladder tissue primarily derived from
bladder cancer patients is not simple [6]. Although we
have used macroscopically tumor-free tisse specimens,
reference genes could be altered by the adjacent path-
ology. First, we have used the most commonly used ref-
erence gene, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). This, however, may be up-regulated in blad-
der cancer [7]. Hence, we also used β-actin (ACTB)
which was not significantly altered in bladder cancer [6]
or prostate cancer [8]. The last reference gene, the gly-
colysis enzyme phosphoglycerate kinase 1 (PGK1), is a
target gene of both the myc oncogene pathway and the
hypoxia inducible factor 1α (HIF-1α) and is therefore
considered as a marker gene for a number of malignant
tissues such as kidney cancer [9] or colon cancer [10].
Recently, HIF-1α activation and subsequent PGK1 up-
regulation has also been demonstrated in bladder cancer
[11]. Taken together, cancer-associated up-regulation of
the reference genes used in the present study was (i) def-
initely present (PGK1), (ii) vaguely present (GAPDH) or
(ii) absent (ACTB). As a consequence, altered target
gene expression was only accepted to be relevant when
it could consistently be observed with all three reference
genes.
Obviously, the target genes may also be altered by the
malignant pathology present in the vast majority of
cases. While care was taken to dissect tissue from the
macroscopically healthy bladder wall with non-infiltrated
urothelium, we cannot exclude the enzyme expression
to be altered in detrusor tissue from bladder cancer pa-
tients. At least, the non-selective ROCK inhibitor HA-
1077 has been found to be beneficial against urothelial
cancer [12] and this finding might be interpreted as an
indication for an enhanced expression of this enzyme in
bladder cancer. However, we did not observe a signifi-
cant correlation between tumor size and ROCK1 or
ROCK2 mRNA expression.
First, our data demonstrated that transcript levels for
ROCK (i.e. ROCK1 and ROCK2 together) were similar
to that for MLCK. Hence on the transcriptional level,
both key enzymes were equally expressed. This is im-
portant to note, since it is consistent with functional
data from cholinergic contractions of human detrusor
specimens that showed an equal pharmacological effect
of ROCK and MLCK inhibition, respectively [5]. Thus,
both enzymes are not only equally transcribed, but also
equally involved on the functional level. Moreover, the
present study has also shown that ROCK2 mRNA is sig-
nificantly more abundant than ROCK1 mRNA. Hence,
the predominant Rho kinase isoform in the human de-
trusor is ROCK2. This is in contrast to rat detrusor tis-
sue, which showed equal transcript levels for ROCK1
and ROCK2 [13]. The predominance of ROCK2 in the
human detrusor is a clinically relevant finding, since Rho
kinase inhibitors are currently developed for different
potential indications, and research so far has largely
been concentrated on the ROCK1 isoform – in particu-
lar in vascular smooth muscle. The notion that this iso-
form is implicated in arterial hypertension [14] has
launched substantial pharmaceutical interest in develop-
ing ROCK1 inhibitors as a new class of antihypertensive
medication [15]. Moreover, increased ROCK function
was also found to be involved in pulmonary hyperten-
sion, and again transcription levels of ROCK1 were more
markedly enhanced than transcription levels of ROCK2
in both rat [16] and human [17]. Currently, specific
ROCK2 inhibitors are not available, but the present
study suggests that ROCK2 might be regarded as poten-
tial therapeutic target in overactive bladder syndrome.
Another major finding was that the ROCK-to-MLCK
ratio showed a significant negative correlation with
aging, even though there was no correlation between
any of these genes and age. In other words, within a
given subject, there was a relative ROCK down-
regulation and – at the same time – MLCK up-
regulation. This was clearly an unexpected finding, since
ROCK contribution to contraction increased with aging
as opposed to the contribution of MLCK [5]. Given the
fact that the down-regulation of ROCK in the aged de-
trusor was primarily due to down-regulation of ROCK2,
Table 3 Pearson’s correlation coefficients between target gene
(ROCK1, ROCK2 and MLCK, ROCK-to-MLCK ratios) and age using
three different reference genes
Target gene Reference genes
GAPDH ACTB PGK1
ROCK1 (n = 41) −0.0043 −0.1584 −0.0732
only male subjects (n = 33) −0.0375 −0.1577 −0.1596
ROCK2 (n = 41) −0.1436 −0.0733 0.0812
only male subjects (n = 33) −0.0884 −0.0404 0.0810
MLCK (n = 21) 0.0201 −0.4151* 0.0593
only male subjects (n = 18) 0.2899 −0.3549 0.0371
ROCK1-to-MLCK ratio (n = 21) −0.2996 −0.3325 −0.3839*
only male subjects (n = 18) −0.2802 −0.4389* −0.5364*
ROCK2-to-MLCK ratio (n = 21) −0.4757* −0.4427* −0.4298*
only male subjects (n = 18) −0.4246* −0.4694* −0.5854**
ROCK-to-MLCK ratio (n = 21) −0.5297** −0.4352* −0.5181**
only male subjects (n = 18) −0.4625* −0.4981* −0.6126**
Correlation coefficients in bold indicate that statistical significance was
reached using all reference genes (*P < 0.05, **P < 0.01; t-test)
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one can speculate about the mechanism of this age-
dependent transcriptional alteration. We already know
from rodent studies that Rho kinase is involved in blad-
der hyperactivity [18], but in addition, it was always the
ROCK1 isoform that was identified to be up-regulated
in rat decompensated detrusor hypertrophy [19] or in al-
tered detrusor contractility of diabetic rabbits [20]. Thus,
down-regulation of ROCK2 in aged human detrusor tis-
sue is therefore a rather uncommon example of tran-
scription regulation, and possibly not the primary cause.
It is therefore intriguing to speculate whether transcrip-
tional ROCK2 down-regulation might be secondary in
order to compensate for an enhanced Rho kinase func-
tion in the aging bladder. Further studies are needed to
address this question experimentally.
Conclusion
The present study shows that ROCK and MLCK are in-
versely regulated and that down-regulation of ROCK –
and in particular ROCK2 – as occurs during aging is
counterbalanced by an up-regulation of MLCK. In con-
clusion, we suggest that there is a physiological homeo-
static regulation of both enzymes which is probably
disturbed in the aged detrusor. Therefore, pharmaco-
logical intervention such as specific ROCK2 inhibitors
might be beneficial to reduce bladder overactivity in the
elderly.
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Fig. 3 The ROCK-to-MLCK ratio is negatively correlated with age. a Relative mRNA content for the target gene MLCK, normalized to reference
genes GAPDH, ACTB and PGK1 plotted against the patients’ age (n = 21). There was no consistent correlation between MLCK and age. b
Ratio of ROCK expression to MLCK expression, plotted gainst age (n = 21). Note that there was a significant negative correlation between
the ROCK-to-MLCK ratio and age using all three reference genes
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